Molecular diagnostics for cardiovascular disease

Clinical Chemistry and Laboratory Medicine

Volumn 36, Issue 8, 1998, Pages 605-614

  Pang, Chi Pui ^a  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Cardiovascular diseases; Molecular diagnosis

Indexed keywords

CARDIOVASCULAR DISEASE; CONFERENCE PAPER; COST EFFECTIVENESS ANALYSIS; DIAGNOSTIC APPROACH ROUTE; HUMAN; MOLECULAR GENETICS; MUTATION; POPULATION GENETICS; PREVALENCE; PRIORITY JOURNAL;

CARDIOVASCULAR DISEASES; FOUNDER EFFECT; GENETIC PREDISPOSITION TO DISEASE; HETEROZYGOTE DETECTION; HUMANS; HYPERLIPIDEMIAS; MUTATION; POLYMERASE CHAIN REACTION; POLYMORPHISM, SINGLE-STRANDED CONFORMATIONAL; SENSITIVITY AND SPECIFICITY;

EID: 0031719866     PISSN: 14346621     EISSN: None     Source Type: Journal    
DOI: 10.1515/CCLM.1998.106     Document Type: Conference Paper

References (94)

1. Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature 1993; 362:801-9.
2. Goldbourt U, Neufeld HN. Genetic aspects of arteriosclerosis. Arteriosclerosis 1986; 6:357-77.
3. Houlston RS, Humphries SE. Coronary risk factors in future: genetics of lipoprotein metabolism. In: Lorimer AR, Shepherd J, editors. Preventive cardiology. Oxford: Blackwell 1991: 30-54.
4. Taylor SI. Diabetes mellitus. In: Scriver CR, Beaudet AL, Sly WS, Valle D, editors. The metabolic basis of inherited disease. New York: McGraw-Hill 1995:843-96.
5. Galton DJ. Genetic determinants of atherosclerosis-related dyslipidemias and their clinical implications. Clin Chim Acta 1997; 257:181-97.
6. Keating MT, Sanguinetti MC. Molecular genetic insights into cardiovascular disease. Science 1996; 272:681-5.
7. Humphries SE. The application of molecular biology techniques to the diagnosis of hyperlipidaemia and other risk factors for cardiovascular disease. Clin Chim Acta 1993; 216:55-18.
8. Schuster H, Luft FC. Clinical criteria versus DNA diagnostics in heterozygous familial hypercholesterolemia. Is molecular diagnosis superior to clinical diagnosis? Arterioscler Thromb Vasc Biol 1998; 18:331-2.
9. Visvikis S, Cambou JP, Arveiler D, Evans AE, Parra HJ, Aguillon D, et al. Apolipoprotein B signal peptide polymorphism in patients with myocardial infarction and controls. Hum Genet 1993; 90:561-5.
10. Saha N, Tay JSH, Chew LS. Influence of apolipoprotein B signal peptide insertion/deletion polymorphism on serum lipids and apolipoproteins in Chinese. Clin Genet 1992; 41:152-6.
11. Renges H-H, Wile DB, McKeigue PM, Marmot MG, Humphries SE. Apolipoprotein B gene polymorphisms associated with lipid levels in men of South Asian descent. Atherosclerosis 1991; 91:267-75.
12. Erlich HA. PCR Technology: principles and application for DNA amplification. London: MacMillan Publishers Ltd, UK, 1989.
13. Rolfs A, Schuller I, Finckh U, Weber-Rolfs. PCR: clinical diagnostics and research. Berlin Heidelberg: Springer-Verlag, 1992.
14. Gille C, Grade K, Coutelle C. A pooling strategy for heterozygote screening of the AF508 cystic fibrosis mutation. Human Genet 1991; 86:289-91.
15. 1-antitrypsin Z and S mutations. Clin Chem 1997; 43:403-4.
16. Newton CR, Graham A, Heptinstall LE. Analysis of any point mutation in DNA. The amplication refractory system (ARMS). Nucleic Acids Res 1989; 17:2503-16.
17. Humphries SE, Gudnason V, Whittall R, Day INM. Single-strand conformation polymorphism analysis with high throughput modifications, and its use in mutation detection in familial hypercholesterolemia. Clin Chem 1997; 43:427-35.
18. Day INM, Whittall R, Gundason V, Humphries SE. Dried template DNA, and dried PCR oligonucleotides and mailing in 96-well plates: LDL receptor gene mutation screening. BioTechniques 1995; 47:68-74.
19. Hayashi K, Yandell DW. How sensitive is PCR-SSCP? Hum Mutat 1993; 2:238-46.
20. Beck S, Pohjl FM. DNA sequencing with direct blotting electrophoresis. EMBO J 1984; 3:2905-9.
21. Goldstein JL, Hobbs HH, Brown MS. Familial hypercholesterolemia. In: Scriver CR, Beaudet AL, Sly WS, Valle D, editors. The metabolic basis of inherited disease. New York: McGraw-Hill 1995:1981-2030.
22. Hobbs HH, Brown MS, Goldstein JL. Molecular genetics of the LDL receptor gene in familial hypercholesterolemia. Hum Mutat 1992; 1:445-66.
23. Koivisto PVI, Koivisto UM, Miettinen TA, Kontula K. Diagnosis of heterozygous familial hypercholesterolemia DNA analysis complements clinical examination and analysis of serum lipid levels. Arterioscler Thromb 1992; 12:584-92.
24. Kwiterovich PO Jr. Genetics and molecular biology of familial combined hyperlipidemia. Curr Opin Lipidology 1993; 4:133-43.
25. Franceschini G. Apolipoprotein function in health and disease: insights from natural mutations. Eur J Clin Invest 1996; 26:733-46.
26. Porkka KVK, Nuotio I, Pajukanta P, Ehnholm C, Suurinkeroinen L, Syvanne M, et al. Phenotype expression in familial combined hyperlipidemia. Atherosclerosis 1997; 133: 245-53.
27. Fisher RM, Humphries SE, Talmud PJ. Common variation in the lipoprotein lipase gene: effects on plasma lipids and risk of atherosclerosis. Atherosclerosis 1997; 135:145-9.
28. Wojciechowski AP, Farrall M, Cullen P, Wilson TME, Bayliss JD, Farren B, et al. Familial combined hyperlipidamia linked to the apolipoprotein AI-CIII-AIV gene cluster on chromosome 11q23-q24. Nature 1991; 349:161-4.
29. Fojo SS, Brewer HB. Hypertriglyceridaemia due to genetic defects in lipoprotein lipase and apolipoprotein CII. J Intern Med 1992; 231:669-77.
30. Reina M, Brunzell JD, Deeb SS. Molecular basis of familial chylomicronaemia: mutations in the lipoprotein lipase and apolipoprotein CII genes. J Lipid Res 1992; 33:1823-32.
31. Hong SH, Woo HP, Chung CL, Jung HS, Jin QM. Association between genetic variations of apoAI-CIII-AIV cluster gene and hypertriglyceridaemic subjects. Clin Chem 1997; 43:13-7.
32. Benlian P, Gennes J, Foubert L, Zhang H, Gagne S, Hayden M. Premature atherosclerosis in patients caused by mutations in the lipoprotein lipase gene. N Engl J Med 1996; 335:848-54.
33. Pimstone SN, Gagne SE, Gagne C, Lupien PJ, Gaudet D, Williams RR, et al. Mutations in the gene for lipoprotein lipase. A cause for low HDL cholesterol levels in individuals heterozygous for familial hypercholesterolaemia. Arterioscler Thromb Vasc Biol 1995; 15:1704-12.
34. Brunzell JD. Familial lipoprotein lipase deficiency and other causes of the chylomicronaemia syndrome. In: Scriver CR, Beaudet AL, Sly WS, Valle D, editors. The metabolic basis of inherited disease. 6th ed. New York: McGraw-Hill, 2:1913-32.
35. Ma Y, Henderson HE, Murthy V, Roederer G, Monsalve MV, et al. A mutation in the human lipoprotein lipase gene as the most common cause of familial chylomiczonaemia in French Canadians. N Engl J Med 1991; 324:1761-6.
36. Funke N, von Eckardstein A, Pritchard PH. A molecular defect causing fish eye disease: an amino acid exchange in lecithin-cholesterol acyltransferase (LCAT) leads to the selective loss of α-LCAT activity. Proc Natl Acad Sci USA 1991; 88:4855-9.
37. Lalouel JM, Wilson DE, Iverius PH. Lipoprotein lipase and hepatic triglyceride lipase: molecular and genetic aspects. Curr Opin Lipidol 1992; 3:86-95.
38. Inazu A, Brown ML, Hesler CB. Increased high density lipoprotein levels caused by a common cholesterol-ester transfer protein gene mutation. N Engl J Med 1990; 323:1234-8.
39. Meiner V, Landsberger D, Berkman N. A common Lithuanian mutation causing familial hypercholesterolaemia in Ashkenazi Jews. Am J Hum Genet 1991; 49:443-9.
40. Hobbs HH, Brown MS, Goldstein JL, Russell DW, Davignon J, Goldstein JL. Deletion in the gene for the LDL receptor in majority of French Canadians with familial hypercholesterolemia. N Engl J Med 1987; 317:734-7.
41. Leitersdorf E, van der Westhuyzen, Coetzee GA, Hobbs HH. Two common LDL receptor gene mutations cause familial hypercholesterolaemia in Afrikaners. J Clin Invest 1989; 84:954-61.
42. Kotze MJ, Langenhoven E, Warnich L, Du Plessis L, Retief A. The molecular basis and diagnosis of familial hypercholesterolemia in South African Afrikaners. Ann Hum Genet 1991; 55:115-21.
43. Lehrman MA, Schneider WJ, Brown MS, Davis CG, Elhammer A, Russell DW, Goldstein JL. The Lebanese allele at the LDL receptor locus: nonsense mutation produces truncated receptor that is retained in endoplasmic reticulum. J Biol Chem 1987; 262:401-10.
44. Vuorio AF, Turtola H, Kontula K. Neonatal diagnosis of familial hypercholesterolemia in newborns born to a parent with molecularly defined heterozygous familial hypercholesterolemia. Arterioscler Thromb Vasc Biol 1997; 17; 3332-7.
45. Gudnason V, King-Underwood L, Soutar AK, Sun X-M, Munro A, Humphries SE. Screening for reported mutations in exon 4 of the low density lipoprotein receptor gene in patients with familial hypercholesterolaemia in the UK. Arterioscler Thromb 1993; 13:56-63.
46. Tybjaerg-Hansen A, Humphries SE. Familial defective apo B100: a single mutation that causes hyperlipidaemia and premature coronary artery disease. Atherosclerosis 1992; 96:91-107.
47. Soria LF, Ludwig E, Clarke HRG, Vega GL, Grundy SM, McCarthy BJ. Association between a specific apolipoprotein B mutation and familial defective apolipoprotein B-100. Proc Natl Acad Sci USA 1989; 86:587-91.
48. Pullinger CR, Hennessy LK, Chatterton JE, Liu W, Love JA, Mendel CM, et al. Familial ligand-defective apolipoprotein B: identification of a new mutation that decreases LDL receptor binding affinity. J Clin Invest 1995; 95:1225-34.
49. Yamakawa-Kobayashi K, Kobayashi T, Obara T, Hamaguchi H. Four new nucleotide sequence polymorphisms in the LDL receptor gene detected by SSCP analysis. Hum Genet 1993; 92:76-8.
50. Maruyama T, Miyake Y, Tajima S, Harada-Shiba M, Yamamura T, et al. Common mutations in the low-density-lipoprotein-receptor gene causing familial hypercholesterolemia in the Japanese population. Arterioscler Thromb 1995; 15:1713-8.
51. Cai HJ, Fan L, Sun X, Chen Q. LDL receptor research in China. Chinese Med J 1995; 108:177-82.
52. Bersot TP, Russell SJ, Thatcher SR, Pomernacki NK, Mahley RW, Weisgraber KH, et al. A unique haplotype of the apolipoprotein B-100 allele associated with familial defective apolipoprotein B-100 in a Chinese man discovered during s study of the prevalence of this disorder. J Lipid Res 1993; 34:1149-54.
53. Mak YT, Zhang J, Chan YS, Mak TWL, Tomlinson B, Masarei JRL, Pang CP. Possible common mutations in the LDL receptor gene in Chinese. Hum Mutat 1998; Suppl 1:S310-3.
54. Sun XM, Patel DD, Webb JC, Knight BL, Fan L-M, Cai H-J, Soutar AK. Familial hypercholesterolemia in China. Identification of mutations in the LDL-receptor gene that result in a receptor-negative phenotype. Arterioscler Thromb 1994; 14:85-94.
55. Mak YT, Pang CP, Tomlinson B, Zhang J, Chan YS, Mak WL, Masarei JRL. Mutations in the low density lipoprotein receptor gene in Chinese familial hypercholesterolemia patients. Arterioscler Thromb Vasc Biol 1998; In press.
56. Omori K, Vergnes L, Zakin MM, Ochoa A. The apolipoprotein AI-CIII-AIV gene cluster: sequence of the apoCIII-apo AIV intergenic region. Gene 1995; 159:231-4.
57. Zeng Q, Dammerman M, Takada Y, Matsunaga A, Breslow JL, Sasaki J. An apolipoprotien CIII marker associated with hypertriglyceridaemia in Caucasians also confers increased risk in a west Japanese population. Hum Genet 1995; 95:371-5.
58. Dallinga-Thie G, Trip M, Rotter J, Cantor R, Bu X, Lusis A, de Bruin T. Complex genetic contribution of the apo AI-CIII-AIV to familial combined hyperlipidaemia. J Clin Invest 1997; 99:953-61.
59. Peacock RE, Hamsten A, Nilsson-Ehle P, Humphries SE. Associations between lipoprotein lipase gene polymorphisms and plasma correlations of lipids, lipoproteins and lipase activities in young myocardial infarction survivors and age-matched healthy individuals from Sweden. Atherosclerosis 1992; 97:171-85.
60. Wang XL, McCredie RM, Wilcken DEL. Common DNA polymorphisms at the lipoprotein lipase gene. Association with severity of CAD and diabetes. Circulation 1996; 93:1339-45.
61. Reymer PWA, Groenemeyer BJ, Gagne E, Miao L, Appelman EEG, Seidel JC, et al. A frequent occurring mutation in the lipoprotein lipase gene (Asn291Ser) contributes to the expression of familial combined hyperlipidaemia. Hum Mol Genet 1995; 4:1543-9.
62. Hata A, Robertson M, Emi M, Lalouel J. Direct detection and automated seqencing of a common allele after electrophoretic strand separation: identification of a common nonsense mutation in exon 9 of the human lipoprotein lipase gene. Nucleic Acids Res 1990; 18:5407-11.
63. Chen L, Patsch W, Boerwinkle E. Hind III polylmorphism in the lipoprotein lipase gene and plasma lipid phenotypes and carotid artery atherosclerosis. Hum Genet 1996; 98:551-6.
64. Zhang Q, Cavanna J, Windelman BR, Shine B, Gross W, Marz W, Galton DJ. Common genetic variants of lipoprotein lipase that relate to lipid transport in patients with premature coronary artery disease. Clin Genet 1995; 48:293-8.
65. Jemaa R, Fumeron F, Poirier O, Lecerf L, Evans A, Arveiler D, et al. Lipoprotein lipase gene polymorphisms: association with myocardial infarction and lipoprotein levels, the ECTIM study. J Lipid Res 1995; 36:2141-6.
66. Mbewu AD, Durrington PN. Lipoprotein (a): structure properties and possible involvement in thrombogeneis and atherogenesis. Atherosclerosis 1990; 85:1-14.
67. Lackner C, Boerwinkle E, Leffert C, Rahmig T, Hobbs HH. Molecular basis of apolipoprotein (a) isoform heterogeneity revealed by pulse-field gel electrophoresis. J Clin Invest 1991; 87:2153-61.
68. De Knijff P, van den Maagdenberg Arn MJM, Frants RR, Havekes LM. Genetic heterogeneity of apolipoprotein E, its influence on plasma lipid and lipoprotein levels. Hum Genet 1994; 4:178-94.
69. Siest G, Pillot T, Regis-Bailly A, Leninger-Muller B, Steinmetz J, Galteau MM, Visvikis S. Apolipoprotein E: an important gene and protein to follow in laboratory medicine. Clin Chem 1995; 41:1068-86.
70. Mann WA, Meyer N, Weber W, Meyer S, Greten H, Beisiegel U. Apolipoprotein E isoforms and rare muations: parallel reduction in binding to cells and to heparin reflects severity of associated type III hyperlipoproteinaemia. J Lipid Res 1995; 36:517-25.
71. Kannel WB, Cuppies A, D'Agostino RB. Sudden death risk in overt coronary heart diseases: the Framingham study. Am Heart J 1987; 113:799-804.
72. Vincent GM, Timothy KW, Leppert M, Keating M. The spectrum of symptoms and QT intervals in carriers of the gene for the long-QT syndrome. N Engl J Med 1992; 327: 846-52.
73. Wang Q, Curran ME, Splawaki I, Burn TC, Millholland JM, van Raay TJ, et al. Positional cloning of a novel potassium channel gene:KVQT1 mutations cause cardiac arrhythmias. Nat Genet 1996; 12:17-23.
74. Wang Q, Shen J, Splawski I, Atkinson D, Li Z, Robinson JL, et al. SCN5A mutations associated with an inherited cardiac arrhythmia, long QT syndrome. Cell 1995; 80:805-11.
75. Curran ME, Splawski I, Timothy KW, Vincent GM, Green ED, Keating MT. A molecular basis for cardiac arrhythmia: HETG mutations cause long QT syndrome. Cell 1995; 80:795-803.
76. Michels VV, Moll PP, Miller FA, Tajik AJ, Chu JS, Driscoll DJ, et al. The frequency of familial dilated cardiomyopathy in a series of patients with idiopathic dilated cardiomyopathy. N Engl J Med 1992; 326:77-82.
77. Kass S, MacRae C, Graber HL, Sparks EA, McNamara D, Boudoulas H, et al. A gene defect that causes conduction system disease and diliated cariomyopathy maps to chromosome 1p1-1q1. Nat Genet 1994; 7:546-51.
78. Krajinovic M, Pinamonti B, Sinagra G, Vatta M, Severini GM, Milasin J, et al. Linkage of familial dilated cardiomyopathy to chromosome 9. Am J Hum Genet 1995; 57:846-52.
79. Olson TM, Keating MT. Mapping a cardiomyopathy locus to chromosome 3p22-p25. J Clin Invest 1996; 97:528-32.
80. Towbin JA, Hejtmancik JF, Brink P, Gelb B, Zhu XM, Chamberlain JS, et al. X-linked dilated cariomyopathy: molecular genetic evidence of linkage to the Duchenne Muscular Dystrophy (Dystrophin) gene at the Xp21 locus. Circulation 1993; 87:1854-65.
81. Rocchiccioli F, Wanders RJA, Aubourg P, Vianey-Liaud C, Ijlst L, Fabre M, et al. Deficiency of long-chain 3-hydroxyacyl-CoA dehydrogenase: a cause of lethal myopathy and cardiomyopathy in early childhood. Ped Res 1990; 248:657-62.
82. Suomalainen A, Paetau A, Leinonen H, Majander A, Peltonen L, Somer H. Inherited idiopathic dilated cardiomyopathy with multiple deletions of mitochondrial DNA. Lancet 1992; 340:1319-20.
83. Watkins H, Conner D, Thierfelder L, Jarcho JA, MacRae C, McKenna WJ, et al. Mutations in the cardiac myosin binding protein-C gene on chromosome 11 cause familial hypertrophic cardiomyopathy. Nat Genet 1995; 11:434-7.
84. Fananapazir L, Epstein N. Molecular and cellular cardiology: genotype-phenotype correlationsin hypertrophic cardiomyopathy: insights provided by comparisons of kindreds with distinct and identical beta-myosin heavy chain gene mutations. Circulation 1994; 89:22-32.
85. Epstein ND, Cohn GM, Cyran F, Fananapazir L. Differences in clinical expression of hypertrophic cardiomyopathy associated with two distinct mutations in the β-myosin heavy chain gene. Circulation 1992; 86:345-52.
86. Anan R, Greve G, Thierfelder L, Watkins H, McKenna W, Solomon S, et al. Prognostic implications of novel β cardiac myosin heavy chain gene mutations that cause familial hypertrophic cardiomyopathy. J Clin Invest 1994; 93:280-5.
87. Curran ME, Atkinson DL, Ewart AK, Morris CA, Leppert MF, Keating MT. The elastin gene is disrupted by a translocation associated with supravalvular aortic stenosis. Cell 1993; 73:159-68.
88. Ewart A, Morris C, Atkinson D, Jin W, Sternes K, Spallone P, et al. Hemizygosity at the elastin locus in a developmental disorder, Williams syndrome. Nat Genet 1993; 5:11-6.
89. Guttmacher AE, Marchuk DA, White RI Jr. Current concerpts: Hereditary hemorrhagic telangiectasia. N Engl J Med 1995; 333:918-24.
90. McAllister KA, Grogg KM, Johnson DW, Gallione CJ, Baldwin MA, Jackson CE, et al. Endoglin, a TGF-β binding protein of endothelial cells, is the gene for hereditary haemorrphagic telangiectasia type 1. Nat Genet 1994; 8:345-51.
91. Francke U, Berg MA, Tynan K, Brenn T, Liu W, Aoyama T, et al. A Gly1127Ser mutation in an EGF-like domain of the fibrillin-1 gene is a risk factor for ascending aortic aneurysm and dissection. Am J Hum Genet 1995; 56:1287-96.
92. Tromp G, Wu Y, Prockop DJ, Madhatheri SL, Kleineert C, Earley JJ, et al. Sequencing of cDNA from 50 unrelated patients reveals that mutations in the triple-helical domain of type III procollagen are an infrequent cause of aortic aneurysms. J Clin Invest 1993; 91:2539-45.
93. Dietz HC, Pyeritiz RE. Mutations in the human gene for fibrillin-1 (FBN1) in the Marfan syndrome and related disorders. Hum Mol Genet 1995; 4:1799-809.
94. Dietz HC, Cutting GR, Pyeritz RE, Maslen CL, Sakai LY, Corson GM, et al. Marfan syndrome caused by a recurrent de novo missense mutation in the fibrillin gene. Nature 1991; 352:337-9.